BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 14634796)

  • 21. HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA-A2+ cancer patients.
    Ishihara Y; Harada M; Azuma K; Tamura M; Shomura H; Fujii T; Itoh K; Shichijo S
    Int J Oncol; 2004 Apr; 24(4):967-75. PubMed ID: 15010837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival.
    Thomas-Kaskel AK; Zeiser R; Jochim R; Robbel C; Schultze-Seemann W; Waller CF; Veelken H
    Int J Cancer; 2006 Nov; 119(10):2428-34. PubMed ID: 16977630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles.
    Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco MA; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
    Int Immunopharmacol; 2015 May; 26(1):133-8. PubMed ID: 25819666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
    Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients.
    Harada M; Kobayashi K; Matsueda S; Nakagawa M; Noguchi M; Itoh K
    Prostate; 2003 Oct; 57(2):152-9. PubMed ID: 12949939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
    Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
    J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
    Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
    Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen.
    Xue BH; Zhang Y; Sosman JA; Peace DJ
    Prostate; 1997 Feb; 30(2):73-8. PubMed ID: 9051144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
    Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
    Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes.
    Ito M; Shichijo S; Miyagi Y; Kobayashi T; Tsuda N; Yamada A; Saito N; Itoh K
    Int J Cancer; 2000 Nov; 88(4):633-9. PubMed ID: 11058882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen.
    Zhu B; Chen Z; Cheng X; Lin Z; Guo J; Jia Z; Zou L; Wang Z; Hu Y; Wang D; Wu Y
    Clin Cancer Res; 2003 May; 9(5):1850-7. PubMed ID: 12738743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ABCE1, a member of ATP-binding cassette transporter gene, encodes peptides capable of inducing HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes in colon cancer patients.
    Shichijo S; Ishihara Y; Azuma K; Komatsu N; Higashimoto N; Ito M; Nakamura T; Ueno T; Harada M; Itoh K
    Oncol Rep; 2005 May; 13(5):907-13. PubMed ID: 15809757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.
    Sotiropoulou PA; Perez SA; Voelter V; Echner H; Missitzis I; Tsavaris NB; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2003 Dec; 52(12):771-9. PubMed ID: 13680193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles.
    Minami T; Matsueda S; Takedatsu H; Tanaka M; Noguchi M; Uemura H; Itoh K; Harada M
    Cancer Immunol Immunother; 2007 May; 56(5):689-98. PubMed ID: 16937115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.
    Correale P; Walmsley K; Nieroda C; Zaremba S; Zhu M; Schlom J; Tsang KY
    J Natl Cancer Inst; 1997 Feb; 89(4):293-300. PubMed ID: 9048833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy.
    Babiak A; Steinhauser M; Götz M; Herbst C; Döhner H; Greiner J
    Oncol Rep; 2014 Jan; 31(1):384-90. PubMed ID: 24154794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer.
    Noguchi M; Itoh K; Suekane S; Yao A; Suetsugu N; Katagiri K; Yamada A; Yamana H; Noda S
    Cancer Sci; 2004 Jan; 95(1):77-84. PubMed ID: 14720331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells.
    Arndt C; Feldmann A; Töpfer K; Koristka S; Cartellieri M; Temme A; Ehninger A; Ehninger G; Bachmann M
    Prostate; 2014 Sep; 74(13):1347-58. PubMed ID: 25053504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.